Alumis Sees Unusually High Options Volume (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS - Get Free Report) saw unusually large options trading on Monday. Stock investors purchased 5,003 call options on the stock. This is an increase of approximately 147% compared to the typical daily volume of 2,026 call options.

Insiders Place Their Bets

In related news, Director Alan Colowick bought 16,104 shares of the stock in a transaction on Tuesday, April 1st. The shares were bought at an average cost of $6.97 per share, for a total transaction of $112,244.88. Following the purchase, the director now owns 16,104 shares of the company's stock, valued at $112,244.88. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Martin Babler purchased 15,650 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were bought at an average cost of $6.44 per share, with a total value of $100,786.00. Following the completion of the acquisition, the chief executive officer now owns 106,454 shares of the company's stock, valued at approximately $685,563.76. This trade represents a 17.23 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALMS. Rhumbline Advisers grew its holdings in shares of Alumis by 21.7% during the first quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock worth $102,000 after buying an additional 2,949 shares in the last quarter. Wells Fargo & Company MN grew its stake in Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock worth $69,000 after acquiring an additional 3,823 shares during the period. Northern Trust Corp raised its holdings in Alumis by 4.3% in the 4th quarter. Northern Trust Corp now owns 111,326 shares of the company's stock valued at $875,000 after acquiring an additional 4,587 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Alumis by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company's stock worth $891,000 after purchasing an additional 4,808 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Alumis by 33.9% during the fourth quarter. Barclays PLC now owns 24,581 shares of the company's stock worth $193,000 after purchasing an additional 6,221 shares during the last quarter.

Alumis Stock Performance

Alumis stock traded down $0.13 during mid-day trading on Friday, hitting $4.18. 40,939 shares of the company were exchanged, compared to its average volume of 316,640. Alumis has a 12-month low of $3.18 and a 12-month high of $13.53. The business's 50 day simple moving average is $5.52 and its two-hundred day simple moving average is $7.72.

Wall Street Analysts Forecast Growth

ALMS has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alumis in a report on Thursday, March 20th. HC Wainwright dropped their price objective on Alumis from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday. Finally, Oppenheimer began coverage on shares of Alumis in a research report on Thursday, January 30th. They set an "outperform" rating and a $32.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $25.86.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.